510(k) device
Onclarity Self-Collection Kit
Becton, Dickinson and Company · Device For Home Collection And Transport Of Vaginal Specimens By Lay Users For Use In An Approved Hpv Molecular Assay (SEP, Class II) · First FDA decision Apr 2, 2026, newest Apr 2, 2026Cervical cancer and HPV
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
1
Naming "Onclarity Self-Collection"
MAUDE reports
0
Brand "Onclarity Self-Collection", since 2015
PubMed studies
0
Mentioning "Onclarity Self-Collection"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Onclarity Self-Collection Kit
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K260184 · Decided Apr 2, 2026 · 71 days after receipt
Device type: Device For Home Collection And Transport Of Vaginal Specimens By Lay Users For Use In An Approved Hpv Molecular Assay (SEP) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- MolDX: Molecular Assays for the Diagnosis of Cutaneous MelanomaLocal determinationIn effectL39389CGS Administrators, LLCUpdated Apr 6, 2026
- MolDX: Molecular Assays for the Diagnosis of Cutaneous MelanomaLocal determinationIn effectL39373Noridian Healthcare Solutions, LLCUpdated Jan 12, 2026
- MolDX: Molecular Assays for the Diagnosis of Cutaneous MelanomaLocal determinationIn effectL39479WPS Insurance CorporationUpdated Apr 22, 2025
- MolDX: Molecular Assays for the Diagnosis of Cutaneous MelanomaLocal determinationIn effectL39345Palmetto GBAUpdated Jun 16, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "Onclarity Self-Collection", any status and sponsor, newest update first.
- BD Onclarity HPV Assay on the BD COR Instrument: Self-collected Vaginal Swabs ValidationNot yet recruiting
Indiana UniversityAcademic, hospital or other
NCT07909499 · 40 participants (planned) · Start Nov 15, 2026 · Primary completion Dec 15, 2026
Device: BD Cor OnClarity Self-Collection · For: Healthy Subjects; HPV
Sites: Indianapolis, Indiana
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Onclarity Self-Collection", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code SEP
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Onclarity Self-Collection"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code SEP.
- Teal WandTeal Health, Inc. · De Novo 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.